• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by iTeos Therapeutics Inc.

    iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos to Participate in Upcoming Investor Conferences
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Therapeutics Announces $120 Million Registered Direct Offering
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos to Participate in Upcoming Investor Conferences
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Announces 2024 Strategic Priorities and Anticipated Milestones
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos to Participate in Upcoming Investor Conferences
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos to Present at Cowen 43rd Annual Health Care Conference
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos to Present at SVB Securities Global Biopharma Conference
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Provides Business Updates and Clinical Development Plans for 2023
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Tickers ITOS
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.